“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial of dabrafenib and trametinib after surgery to remove melanoma (COMBI-AD)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
The BRAF gene affects how cells divide and grow. Sometimes the gene is changed or damaged. This is called a gene
The first treatment for melanoma is usually surgery. This often cures early stage melanoma. But if melanoma has spread into
In this trial, they are looking at 2 drugs called dabrafenib and trametinib. These are both types of biological therapy called cancer growth blockers. They work by stopping signals that cancer cells use to divide and grow.
The aims of the trial are to
- Find out if having dabrafenib and trametinib together helps to stop melanoma coming back after surgery
- Learn more about the side effects of this drug combination
Who can enter
You may be able to enter this trial if
- You have had a melanoma completely removed with surgery in the last 12 weeks
- Your melanoma had spread into lymph nodes (stage 3A, 3B or 3C) and is considered to be at high risk of coming back (you can also take part if you had early stage melanoma that has now come back in a
lymph nodeand this can be surgically removed)
- You have completely recovered from surgery
- Your melanoma cells have a mutation called V600E/K in the BRAF gene – the trial team will test for this
- You can swallow tablets and capsules
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You have satisfactory blood test results
- You are at least 18 years old
- You are willing to use reliable contraception for 2 weeks before starting the trial drugs, throughout treatment and for 4 months afterwards if there is any chance you could become pregnant
You cannot enter this trial if you
- Have melanoma that started in your eye (ocular melanoma) or in the moist tissues that line your mouth, nose, food pipe, anus, vulva and vagina (
- Have melanoma that has spread to other parts of your body (apart from lymph nodes)
- Have already had a treatment for melanoma that reaches your whole body (a
- Have had another experimental drug in the last 4 weeks (or earlier if there is any chance some of the drug could still be in your body)
- Are known to be very sensitive to drugs similar to those being looked at in the trial
- Have any problems with your
digestive systemthat could affect how you absorb tablets or capsules
- Have conditions affecting your lungs called interstitial lung disease or pneumonitis
- Have certain heart problems or eye conditions – the trial team can advise you about this
- Are lacking in a body substance called G6PD – your doctor can advise you about this
- Are known to be HIV positive
- Have had another cancer in the last 5 years apart from non melanoma skin cancer that was completely removed or a very early stage cancer (
carcinoma in situ) that was successfully treated
- Have any other medical condition or mental health problem that the trial team think could affect you taking part
- Are pregnant or breastfeeding
This phase 3 trial will recruit about 850 people. It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
Half the people take dabrafenib and trametinib together. The other half take dummy drugs (
Dabrafenib is a capsule that you take twice a day. Trametinib is a tablet that you take once a day.
The 2 dummy drugs will look exactly the same as the dabrafenib capsules and the trametinib tablets, and you take them in the same way.
As long as you don’t have bad side effects and your melanoma doesn’t come back, you can carry on having the trial drugs (or dummy drugs) for a year.
The trial team will ask you to fill out a questionnaire before you start treatment, every 3 months for 2 years and then every 6 months after that. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
During the trial, the researchers will take a number of extra blood samples to look for substances called
The trial team will ask to take an extra blood sample to look at how genes affect the way people respond to a drug and the side effects they have. This is called
If you develop a non melanoma skin cancer during the trial, your doctor may ask to take a biopsy of it. Having this biopsy is also optional.
You see the trial team and have some tests before you start treatment. The tests include
- Physical examination including an eye test
- Heart trace (
- Heart scan (
- Blood tests
- CT scan or MRI scan
You then go to hospital
- Once a month in the 1st year
- Every 3 months during the 2nd year
- Every 6 months after that
At each visit you have blood tests and a physical examination. At some visits you also have an eye test, a heart trace, a heart scan and a CT scan.
If your melanoma comes back, you will need to have a CT or MRI scan and blood tests. The trial team may ask you to have another
As dabrafenib and trametinib are new drugs, there may be some side effects we don’t know about yet. In an earlier trial, the most common side effects of having both drugs together were
- High temperature (fever)
- A drop in the number of red and white blood cells that can cause an increased risk of infection, tiredness and breathlessness
- Loss of appetite
- Tummy (abdominal) pain
- Feeling or being sick
- Dry mouth
- Rash, itching and dry, red or scaly skin
- Night sweats
- Pain or stiffness in your joints
- Pain or spasm in your muscles
- Pain in your arms or legs
- Tiredness (fatigue)
- Swelling of your face, hands or feet
- Bladder infection
Your doctor will talk to you about all the possible side effects before you agree to join the trial.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Nathan
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer